Chris Hogg is a Health 2.0 advocate, tech enthusiast and healthcare researcher and analyst. He is interested in how technology is changing the healthcare landscape, specifically the impact it can have on behavioral change. Chris is passionate about the value and utility of new forms of health data, and how data will drive a changing relationship between physician and patient.
In October 2011, Chris Co-founded 100Plus, a personalized health prediction startup using data analytics and game mechanics to show how small changes in behavior can lead to an overall healthier and longer life. 100Plus uses data from large clinical and behavioral datasets from Practice Fusion, an electronic medical record provider, and from the CDC to help users understand how their behaviors impact their future health.
Prior to 100Plus, Chris was the Director of Commercial Strategy at Gilead Sciences, where he was responsible for understanding the evolving therapeutic landscape for cardiovascular diseases, such as coronary artery disease and Type 2 diabetes.
He was also Project Team Leader for Ranexa (Ranolazine), a treatment for Chronic Angina.
Chris has been a guest lecturer at Stanford University and a speaker at TEDx Silicon Valley on the topics of user-generated health and the future of health data. Chris holds a Degree in Molecular and Cell Biology from Brown University and an MBA from The University of Chicago.
|Feb 23, 2016||Vator.tv - See how Vator Splash Heath played out on Twitter|
|Sep 5, 2014||Mass Device - Smart inhaler maker raises $14.5M|
|Sep 4, 2014||Xconomy - Propeller Health Raises $14.5M for Its Respiratory Disease Sensors|
|Aug 7, 2013||TechCrunch - Acorn Fund|
|Jun 4, 2013||Gigaom - Practice Fusion pulls back the curtain on its electronic health data – for a fee|
|May 21, 2013||Venture Beat - What do we mean when we talk about patient engagement?|
|Feb 28, 2013||FinSMEs - Practice Fusion Acquires 100Plus|
|Feb 27, 2013||TechCrunch - Practice Fusion Makes First Acquisition In Thiel-Backed Mobile Health Startup 100Plus To Help It Build Products For Patients|